Testing AHB-171 as a new hepatitis B treatment
Treatments studied
Part of Digestive system, Infections clinical trials.
This study tests a new experimental drug called AHB-171 in people with chronic hepatitis B infection. The trial aims to see how safe the drug is and how well it works to help control the virus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Between 18 and 65 years old with a healthy body weight and BMI (19–35 kg/m²)
- Confirmed hepatitis B infection for at least 6 months before starting the trial
- Normal heart function on screening ECG with no significant abnormalities
- No other serious medical conditions like heart disease, uncontrolled diabetes, or organ transplant history
- No liver disease from other causes, no cirrhosis, and no history of liver cancer
- Not pregnant, not breastfeeding, and willing to use reliable birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, AHB-137, in people with chronic hepatitis B who are already on a stable antiviral treatment. It aims to see if AHB-137 can help lower the virus further or improve outcomes.
This study tests a new medicine called AHB-137 for people with chronic hepatitis B who are HBeAg negative and currently on antiviral therapy. The goal is to see if it can help control the virus better or allow you to stop your current medication safely.
This study tests a new antibody treatment (VIR-3434) for chronic hepatitis B. It aims to see if the antibody can help your immune system control the virus, potentially allowing you to stop your current antiviral medication later.
This study tests whether adding a new drug called HRS-5635 to your current hepatitis B medicine works better than your current treatment alone. You may qualify if your hepatitis B is already controlled with antiviral pills and your viral levels are very low.
This trial tests a new investigational drug called AHB-171 for people with chronic hepatitis B who are already stable on standard antiviral therapy. It aims to see if the drug is safe and may help control the virus better.
This study tests whether a new drug called AHB-171 can help treat chronic hepatitis B (a long-term liver infection). You would receive the drug by injection under your skin and be monitored to see if it helps reduce the hepatitis B virus and improves liver health.
Hear when a new Hepatitis B, Chronic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.